Skip to main content

Research Repository

Advanced Search

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer

Morotti, Matteo; Bridges, Esther; Valli, Alessandro; Choudhry, Hani; Sheldon, Helen; Wigfield, Simon; Gray, Nicki; Zois, Christos E.; Grimm, Fiona; Jones, Dylan; Teoh, Eugene J.; Cheng, Wei-Chen; Lord, Simon; Anastasiou, Dimitrios; Haider, Syed; McIntyre, Alan; Goberdhan, Deborah C. I.; Buffa, Francesca; Harris, Adrian L.

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer Thumbnail


Authors

Matteo Morotti

Esther Bridges

Alessandro Valli

Hani Choudhry

Helen Sheldon

Simon Wigfield

Nicki Gray

Christos E. Zois

Fiona Grimm

Dylan Jones

Eugene J. Teoh

Wei-Chen Cheng

Simon Lord

Dimitrios Anastasiou

Syed Haider

Deborah C. I. Goberdhan

Francesca Buffa

Adrian L. Harris



Abstract

Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α–positive (ERα+) breast cancer. Hypoxia is known to affect tumor growth by reprogramming metabolism and regulating amino acid (AA) uptake. Here, we show that the glutamine transporter, SNAT2, is the AA transporter most frequently induced by hypoxia in breast cancer, and is regulated by hypoxia both in vitro and in vivo in xenografts. SNAT2 induction in MCF7 cells was also regulated by ERα, but it became predominantly a hypoxia-inducible factor 1α (HIF-1α)–dependent gene under hypoxia. Relevant to this, binding sites for both HIF-1α and ERα overlap in SNAT2’s cis-regulatory elements. In addition, the down-regulation of SNAT2 by the ER antagonist fulvestrant was reverted in hypoxia. Overexpression of SNAT2 in vitro to recapitulate the levels induced by hypoxia caused enhanced growth, particularly after ERα inhibition, in hypoxia, or when glutamine levels were low. SNAT2 up-regulation in vivo caused complete resistance to antiestrogen and, partially, anti-VEGF therapies. Finally, high SNAT2 expression levels correlated with hypoxia profiles and worse outcome in patients given antiestrogen therapies. Our findings show a switch in the regulation of SNAT2 between ERα and HIF-1α, leading to endocrine resistance in hypoxia. Development of drugs targeting SNAT2 may be of value for a subset of hormone-resistant breast cancer.

Citation

Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., …Harris, A. L. (2019). Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences, 116(25), 12452-12461. https://doi.org/10.1073/pnas.1818521116

Journal Article Type Article
Acceptance Date May 9, 2019
Online Publication Date May 31, 2019
Publication Date Jun 18, 2019
Deposit Date Dec 17, 2020
Publicly Available Date Apr 23, 2021
Journal Proceedings of the National Academy of Sciences
Print ISSN 0027-8424
Electronic ISSN 1091-6490
Publisher National Academy of Sciences
Peer Reviewed Peer Reviewed
Volume 116
Issue 25
Pages 12452-12461
DOI https://doi.org/10.1073/pnas.1818521116
Keywords Multidisciplinary
Public URL https://nottingham-repository.worktribe.com/output/5154493
Publisher URL https://www.pnas.org/content/116/25/12452

Files




You might also like



Downloadable Citations